Fight Aging!

Senescent cells accumulate with age, a situation that appears more a result of the aging immune system failing to achieve timely clearance of newly senescent cells rather than a significant increase in the pace at which cells become senescent. Senescence occurs in response to cellular damage and stress, but also when somatic cells reach the Hayflick limit on replication. A senescent cell becomes larger, ceases replication, and devotes its energies to the secretion of pro-growth, pro-inflammatory signals. In the short term and in youth this is usually beneficial, helping to coordinate tissue maintenance, regeneration, and suppression of potentially cancerous cells. When sustained for the long term, the signaling of senescent cells is disruptive to tissue structure and function, however, contributing to the damaging chronic inflammation of aging.

In principle, clearing out lingering senescent cells should improve the ability of other classes of rejuvenation therapy to produce benefits. This is particularly thought to be case for stem cell and exosome therapies that rely upon generating favorable signals to improve the behavior of a patient's cells, thereby dampening chronic inflammation and hopefully enhancing regeneration and tissue maintenance. Senescent cells and signaling therapies stand in opposition, and it makes sense that a reduced burden of senescent cells should improve outcomes for signaling therapies.

This has to be tested, of course. Today's open access paper reports on the results from one example of this sort of study. Unfortunately the researchers involved chose to employ accelerated aging mouse models rather than naturally aged mice, so one can't take the results entirely at face value. Still, it is supportive of the consensus view on the opposition between senescent cells and signaling therapies. Interestingly, the researchers used a senolytic vaccine rather than a small molecule; you might recall an earlier study that employed this specific vaccine to slow cancer progression in mice.

Synergistic senolytic-regenerative therapy significantly extends healthspan and lifespan

Regenerative medicine, particularly through stem cell-based therapies, holds immense potential for treating chronic diseases and mitigating the effects of aging by restoring tissue function and homeostasis. Mesenchymal stem cells (MSCs), have been extensively investigated for their paracrine effects, immunomodulatory properties, and capacity to promote tissue repair via secretion of growth factors. Personalized MSC (pMSC) are a type of autologous stem cells developed by Immorta Bio which can be produced in an "age-specific" manner by controlling the extent of differentiation during generation from pluripotent stem cells. MSC are attractive from an anti-aging perspective because of the studies showing young MSC can suppress and in some cases even inhibit characteristics of aging.

Despite promising preclinical outcomes, and one FDA approval for an orphan disease, clinical translation of MSC therapeutics remains limited, with many trials demonstrating modest efficacy in conditions characterized by fibrosis, inflammation, and organ failure. A key barrier to successful regeneration is the accumulation of senescent cells, a hallmark of aging and chronic pathology that actively impedes stem cell function. Senescent cells, induced by stressors such as oxidative damage, telomere attrition, or chemotherapeutic agents, enter a state of irreversible cell cycle arrest and secrete a constellation of pro-inflammatory cytokines, chemokines, and matrix-degrading proteins collectively known as the senescence-associated secretory phenotype (SASP). SASP components not only perpetuate local inflammation but also directly antagonize regenerative processes by inhibiting stem cell proliferation, differentiation, and survival.

Experimental models of organ failure and accelerated aging, including carbon tetrachloride (CCl4)-induced hepatotoxicity and doxorubicin chemotherapy, reliably recapitulate this senescent environment, manifesting as increased aging markers and impaired physical capacity alongside biochemical evidence of tissue damage. Here, we investigate the hypothesis that senescent cells and their SASP directly impair pMSC-mediated regeneration in models of liver failure and accelerated aging. Using SenoVax, a novel senolytic immunotherapy, in combination with pMSCs, we evaluate synergistic effects on biochemical markers of liver function, aging and regenerative biomarkers, survival, and physical fitness attributes of aging. Combined senolytic and pMSC therapy outperformed monotherapies and produced clear synergistic benefits, including significant biochemical improvement of liver failure parameters, reversal of accelerated aging features, and restoration of regenerative signaling pathways. These findings support the concept that clearance of senescent cells can act as a critical adjuvant to regenerative therapies for chronic disease and aging.